Abstract
Cytomegalovirus (CMV) remains a significant contributor to morbidity and death after pediatric solid and stem cell transplantation. Decisions regarding prevention and treatment often lack pediatric-specific data to drive decision making. We present here a case-based discussion around some of these specific topics and focus on approaches to CMV prevention, post-CMV secondary prophylaxis options, and identification and treatment of resistant CMV infection, including emerging antiviral agents and the use of cytotoxic CMV-specific T-cells, in the setting of pediatric hematopoietic stem cell transplantation.
MeSH terms
-
Antiviral Agents / therapeutic use
-
Child
-
Cytomegalovirus / immunology
-
Cytomegalovirus Infections / complications
-
Cytomegalovirus Infections / prevention & control*
-
Cytomegalovirus Infections / virology
-
Drug Resistance, Viral
-
Fatal Outcome
-
Foscarnet / therapeutic use
-
Granulomatous Disease, Chronic / complications
-
Granulomatous Disease, Chronic / therapy*
-
Hematopoietic Stem Cell Transplantation*
-
Humans
-
Male
-
Recurrence
-
Respiratory Insufficiency / etiology
-
Risk Assessment
-
Secondary Prevention
-
T-Lymphocytes, Cytotoxic
-
Valganciclovir / therapeutic use
-
Viral Load
Substances
-
Antiviral Agents
-
Foscarnet
-
Valganciclovir